HDAC inhibitor-dependent transcriptome and memory reinstatement in cognitive decline models

Area of Science:

• Neuroscience
• Epigenetics
• Molecular Biology

Background:

• Aging and amyloid pathology are key risk factors for cognitive decline, including Alzheimer's disease (AD).
• Current therapies for these conditions are limited.
• Epigenetic alterations and inflammation play significant roles in cognitive impairment.

Purpose of the Study:

• To investigate transcriptome and epigenome plasticity in mouse models of aging and amyloid deposition.
• To understand the molecular mechanisms underlying age-associated memory impairment and AD pathology.
• To evaluate the therapeutic potential of histone deacetylase (HDAC) inhibitors.

Main Methods:

• Utilized mouse models of age-associated memory impairment and amyloid deposition.
• Analyzed transcriptome and cell type-specific epigenome plasticity in the brain and peripheral organs.
• Assessed the effects of vorinostat, an HDAC inhibitor, on cognitive function, inflammation, and gene expression.

Main Results:

• Aging and amyloid pathology induce inflammation and impair synaptic function in the hippocampus via epigenetic changes.
• Amyloid pathology affects histone acetylation and plasticity gene expression.
• Aging impacts H4K12 acetylation-linked differential splicing in neurons.
• Vorinostat treatment reversed memory deficits, reduced inflammation, and restored epigenetic balance.

Conclusions:

• Epigenetic dysregulation contributes to cognitive decline in aging and AD models.
• HDAC inhibitors like vorinostat demonstrate therapeutic potential for age-associated cognitive impairment.
• Further exploration of HDAC inhibitors is warranted as a cost-effective treatment strategy.